Tests an extended HPV vaccine schedule in young women at higher risk
Compares an extended and a standard HPV vaccine schedule in women aged 18-26.
Plain-language title generated from the registry record
Registry title: Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus Exposure
Key facts
- Where
- Parkville, AustraliaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 26 years old?
Source: NCT06681636, who can take part
Where in Australia
- Murdoch Children Research InstituteParkville, AustraliaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Institute of Hygiene and Epidemiology, Vietnam
- Trial code
- NCT06681636
- Record updated
- 8 November 2024
- Original description
A Study to evaluate if the 3 dose extended schedule (0-6-18 months) for the HPV vaccine Gardasil-9 provide similar immune responses and short term protection against HPV infection compared to the regular 3 dose schedule (0-2-6 months) in high risk women in VietnamRead full original descriptionShow less
A Non-inferiority Study Comparing the Immunogenicity of a Standard or an Extended Three-dose Nonavalent Human Papillomavirus Vaccine Schedule Between High-risk Women Aged 18-26 Years and Age-matched Women in the General Population
A Study to evaluate if the 3 dose extended schedule (0-6-18 months) for the HPV vaccine Gardasil-9 provide similar immune responses and short term protection against HPV infection compared to the regular 3 dose schedule (0-2-6 months) in high risk women in Vietnam
Inclusion: Is between the reporting ages of 18-26 years at the time of recruitment; Engage in commercial sex in the last 6m (for FSW group) or have engaged in sexual activity (non-FSWs); Willing and able to give written informed consent; Willing to complete the follow-up requirements of the study.
Exclusion: Has received any HPV vaccine previously; Currently receiving immunosuppressive medication or anti-cancer chemotherapy; Known allergies to any vaccine component; Known HIV infection; Known Congenital immune deficiency syndrome; Participants meeting any of the following criteria will be excluded from the trial:; Pregnant or possibly pregnant; Has an axillary temperate greater than 38°C; incapacity to provide consent.